FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185595354> ?p ?o ?g. }

• W3185595354 endingPage "3" @default.
• W3185595354 startingPage "3" @default.
• W3185595354 abstract "Introduction: Primary biliary cholangitis (PBC) is a chronic and progressive auto immune disease. Patients with PBC have been treated for a long time only with ursodeoxycholic acid (UDCA), though not all patients responded or tolerated it. Nowadays, a secondline drug has been approved for the treatment of patients with PBC who fail to first-line UDCA therapy, showing improvements on liver biochemistry. Thus, we want to describe our experience in realworld clinical practice. The main aim of the treatment is to increase transplantfree survival, while the secondary objectives are to slow down the liver disease progression and to diminish PBCassociated symptoms. Method: Prospective study which evaluates the efficacy and safety of obeticholic acid (OCA) in a realworld subset of patients. The primary aim was to assess changes in alkaline phosphatase (ALP). The secondary objectives were to iden tify changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), gammaglutamyl transpeptidase (GGT), albumin and bilirubin, the reason for start ing the treatment, the dose of obeticholic acid, drug interactions, the adverse effects detected and the budgetary impact at our hospital. Result: We enrolled 14 patients, 85.7% women with a mean age of 54 ±8 years. 28.6% of patients had liver fibrosis stage 0-1. The mean duration of obeticholic acid therapy was 14 ±5 months, with >90% adherence. All patients maintained dual therapy with UDCA. 42.9% of patients received 5 mg/day of obeticholic acid, and in 57.1% the dose was titrated to 10 mg/day after six months of treat ment due to lack of response. All patients reduced their ALP values and 92.9% reduced their ALT. The mean percentages of reduction were 34% for ALP, 36% for ALT, 27% for AST, 2% for albumin and 44% for GGT. After starting treat ment, pruritus was worsened in three patients, interrupting the therapy in only one case. The cost of obeticholic acid treatment for PBC is €26,449/patient/year, and the treatment of these patients involved a cost of €264,490, which was the 3.1% of the total budget of the Gastrointestinal Department in 2019. Conclusion: Obeticholic acid is a drug with a high budgetary impact that has shown similar effectiveness in the real world to that achieved in clinical trials, improving ALP and ALT levels in primary biliary cholangitis patients" @default.
• W3185595354 created "2021-08-02" @default.
• W3185595354 creator A5012613732 @default.
• W3185595354 creator A5032370865 @default.
• W3185595354 creator A5033055030 @default.
• W3185595354 creator A5066356415 @default.
• W3185595354 creator A5066517356 @default.
• W3185595354 date "2021-01-01" @default.
• W3185595354 modified "2023-09-23" @default.
• W3185595354 title "Real-world results of the use of obeticholic acid in the treatment of primary biliary cholangitis" @default.
• W3185595354 hasPublicationYear "2021" @default.
• W3185595354 type Work @default.
• W3185595354 sameAs 3185595354 @default.
• W3185595354 citedByCount "0" @default.
• W3185595354 crossrefType "journal-article" @default.
• W3185595354 hasAuthorship W3185595354A5012613732 @default.
• W3185595354 hasAuthorship W3185595354A5032370865 @default.
• W3185595354 hasAuthorship W3185595354A5033055030 @default.
• W3185595354 hasAuthorship W3185595354A5066356415 @default.
• W3185595354 hasAuthorship W3185595354A5066517356 @default.
• W3185595354 hasConcept C126322002 @default.
• W3185595354 hasConcept C160160445 @default.
• W3185595354 hasConcept C170493617 @default.
• W3185595354 hasConcept C181199279 @default.
• W3185595354 hasConcept C185592680 @default.
• W3185595354 hasConcept C197934379 @default.
• W3185595354 hasConcept C203092338 @default.
• W3185595354 hasConcept C2777067796 @default.
• W3185595354 hasConcept C2777075537 @default.
• W3185595354 hasConcept C2778938600 @default.
• W3185595354 hasConcept C2779399885 @default.
• W3185595354 hasConcept C2780965833 @default.
• W3185595354 hasConcept C535046627 @default.
• W3185595354 hasConcept C55493867 @default.
• W3185595354 hasConcept C71924100 @default.
• W3185595354 hasConcept C90924648 @default.
• W3185595354 hasConceptScore W3185595354C126322002 @default.
• W3185595354 hasConceptScore W3185595354C160160445 @default.
• W3185595354 hasConceptScore W3185595354C170493617 @default.
• W3185595354 hasConceptScore W3185595354C181199279 @default.
• W3185595354 hasConceptScore W3185595354C185592680 @default.
• W3185595354 hasConceptScore W3185595354C197934379 @default.
• W3185595354 hasConceptScore W3185595354C203092338 @default.
• W3185595354 hasConceptScore W3185595354C2777067796 @default.
• W3185595354 hasConceptScore W3185595354C2777075537 @default.
• W3185595354 hasConceptScore W3185595354C2778938600 @default.
• W3185595354 hasConceptScore W3185595354C2779399885 @default.
• W3185595354 hasConceptScore W3185595354C2780965833 @default.
• W3185595354 hasConceptScore W3185595354C535046627 @default.
• W3185595354 hasConceptScore W3185595354C55493867 @default.
• W3185595354 hasConceptScore W3185595354C71924100 @default.
• W3185595354 hasConceptScore W3185595354C90924648 @default.
• W3185595354 hasIssue "2" @default.
• W3185595354 hasLocation W31855953541 @default.
• W3185595354 hasOpenAccess W3185595354 @default.
• W3185595354 hasPrimaryLocation W31855953541 @default.
• W3185595354 hasVolume "23" @default.
• W3185595354 isParatext "false" @default.
• W3185595354 isRetracted "false" @default.
• W3185595354 magId "3185595354" @default.
• W3185595354 workType "article" @default.